Modera Wealth Management LLC Acquires 3,217 Shares of Zoetis Inc. (NYSE:ZTS)

Modera Wealth Management LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 12.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 29,641 shares of the company's stock after acquiring an additional 3,217 shares during the period. Modera Wealth Management LLC's holdings in Zoetis were worth $4,829,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZTS. Callahan Advisors LLC boosted its stake in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after purchasing an additional 6,221 shares during the period. Pensionfund Sabic raised its position in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after buying an additional 4,000 shares during the period. CIBC Asset Management Inc lifted its stake in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after acquiring an additional 46,050 shares in the last quarter. PFW Advisors LLC acquired a new stake in Zoetis during the 4th quarter worth about $1,764,000. Finally, Alberta Investment Management Corp grew its stake in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock valued at $4,904,000 after acquiring an additional 28,700 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $2.94 during trading hours on Wednesday, hitting $166.96. 3,667,422 shares of the stock were exchanged, compared to its average volume of 3,280,360. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The company's 50 day moving average is $166.53 and its 200 day moving average is $177.06. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market capitalization of $74.76 billion, a P/E ratio of 30.52, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis's dividend payout ratio is 36.56%.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. StockNews.com cut shares of Zoetis from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.